



SPECIAL ARTICLE

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort



S. Koirala^{a,*}, S. Borisov^{b,*}, E. Danila^{c,*}, A. Mariandyshev^d, B. Shrestha^e, N. Lukhele^f, M. Dalcolmo^g, S.R. Shakya^h, S. Miliuskasⁱ, L. Kuksa^j, S. Manga^k, A. Aleksa^l, J.T. Denholm^m, H.B. Khadkaⁿ, A. Skrahina^o, S. Diktanas^p, M. Ferrarese^q, J. Bruchfeld^r, A. Koleva^s, A. Piubello^t, G.S. Koirala^u, Z.F. Udwadia^v, D.J. Palmero^w, M. Munoz-Torrico^x, R. GC^y, G. Gualano^z, V.I. Grecu^A, I. Motta^B, A. Papavasileiou^C, Y. Li^D, W. Hoefsloot^E, H. Kunst^F, J. Mazza-Stalder^G, M.-C. Payen^H, O.W. Akkerman^{I,J}, E. Bernal^K, V. Manfrin^L, A. Matteelli^M, H. Mustafa Hamdan^N, M. Nieto Marcos^O, J. Cadiñanos Loidi^P, J.J. Cebrian Gallardo^Q, R. Duarte^R, N. Escobar Salinas^S, R. Gomez Rosso^T, R. Laniado-Laborín^{U,V}, E. Martínez Robles^W, S. Quirós Fernandez^X, A. Rendon^Y, I. Solovic^Z, M. Tadolini^{aa,bb}, P. Viggiani^{cc}, E. Belilovski^b, M.J. Boeree^E, Q. Cai^{dd}, E. Davidavičienė^{ee,ff}, L.D. Forsman^r, J. De Los Rios^{gg}, J. Drakšienė^P, A. Duga^{hh,ii}, S.E. Elamin^N, A. Filippov^b, A. Garcia^w, I. Gaudiesiuteⁱ, B. Gavazova^{jj}, R. Gayoso^g, V. Gruslys^c, J. Jonsson^{kk}, E. Khimova^d, G. Madonsela^{ll}, C. Magis-Escurrea^E, V. Marchese^M, M. Matei^{mm,nn}, C. Moschos^C, B. Nakčerienė^{ee,ff}, L. Nicod^G, F. Palmieri^z, A. Pontarelli^{oo}, A. Šmite^j, M.B. Souleymane^t, M. Vescovo^w, R. Zablockis^c, D. Zhurkin^o, J.-W. Alffenaar^{pp,qq,rr}, J.A. Caminero^{ss,tt}, L.R. Codecasa^q, J.-M. García-García^{uu}, S. Esposito^{vv}, L. Saderi^{ww}, A. Spanevello^{xx,yy}, D. Visca^{xx,yy}, S. Tiberi^{F,zz}, E. Pontali^{AA}, R. Centis^{BB}, L. D'Ambrosio^{CC}, M. van den Boom^{DD}, G. Sotgiu^{ww}, G.B. Migliori^{BB,*}

^a Damien Foundation Nepal, Kathmandu, Nepal

^b Moscow Research and Clinical Center for TB Control, Moscow Government's Health Department, Moscow, Russian Federation

^c Clinic of Chest Diseases, Immunology and Allergology, Vilnius University Medical Faculty, Centre of Pulmonology and Allergology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

^d Northern State Medical University, Northern (Arctic) Federal University, Arkhangelsk, Russian Federation

^e Kalimati Chest Hospital/GENETUP/Nepal Anti Tuberculosis Association, Kathmandu, Nepal

^f TB/HIV, Hepatitis, & PMTCT Department, World Health Organization, Eswatini WHO Country Office, Mbabane, Eswatini

^g Reference Center Hélio Fraga, Fundação Oswaldo Cruz (Fiocruz)/Ministry of Health, Rio de Janeiro, Brazil

^h Lumbini Provincial Hospital, Butwal, Nepal

* Corresponding author at: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy.

E-mail address: giovannibattista.migliori@icsmaugeri.it (G.B. Migliori).

* These authors equally contributed

ⁱ Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania
^j MDR-TB Department, Riga East University Hospital for TB and Lung Disease Centre, Riga, Latvia
^k Department of Infectious Diseases, University National San Antonio Abad Cusco, Cusco, Peru
^l Department of Phthisiology and Pulmonology, Grodno State Medical University, Grodno, Belarus
^m Victorian Tuberculosis Program, Melbourne Health, Department of Infectious Diseases, University of Melbourne, Melbourne, Australia
ⁿ Nepalgunj TB Referral Center, TB Nepal, Nepalgunj, Nepal
^o Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus
^p Tuberculosis Department, 3rd Tuberculosis Unit, Republican Klaipėda Hospital, Klaipėda, Lithuania
^q TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy
^r Division of Infectious Diseases, Department of Medicine, Solna, Karolinska Institute, Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
^s Pulmonology and Physiotherapy Department, Gabrovo Lung Diseases Hospital, Gabrovo, Bulgaria
^t Damien Foundation, Niamey, Niger
^u Nepal Anti Tuberculosis Association, Morang Branch, TB Clinic, Biratnagar, Province 1, Nepal
^v Department of Respiratory Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India
^w Pulmonology Division, Municipal Hospital F. J. Muñoz, Buenos Aires, Argentina
^x Clínica de Tuberculosis, Instituto Nacional De Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad De Mexico, Mexico
^y Damien Foundation, Midpoint District Community Memorial Hospital, Danda, Nawalparasi, Nepal
^z Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy
^A National Programme for Prevention, Surveillance and Control of Tuberculosis, Dolj Province, Romania
^B Department of Medical Science, Unit of Infectious Diseases, University of Torino, Italy
^C Department of Tuberculosis, Sotiria Athens Hospital of Chest Diseases, Athens, Greece
^D Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
^E Radboud University Medical Center, Center Dekkerswald, Nijmegen, The Netherlands
^F Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
^G Division of Pulmonary Medicine, University Hospital of Lausanne CHUV, Lausanne, Switzerland
^H Division of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
^I University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands
^J University of Groningen, University Medical Center Groningen, TB Center Beatrixoord, Haren, The Netherlands
^K Unidad de Enfermedades Infecciosas, Hospital General Universitario Reina Sofia, Murcia, Spain
^L Infectious and Tropical Diseases Operating Unit, S. Bortolo Hospital, Vicenza, Italy
^M Clinic of Infectious and Tropical Diseases, WHO Collaborating Centre for TB Elimination and TB/HIV Co-infection, University of Brescia, Brescia, Italy
^N MDR-TB Department, Abu Anga Teaching Hospital, Khartoum, Sudan
^O Internal Medicine Department, Hospital Doctor Moliner, Valencia, Spain
^P Internal Medicine Department, Hospital General de Villalba, Collado Villalba, Spain
^Q Unidad de Neumología, Agencia Sanitaria Costa del Sol, Marbella, Spain
^R National Reference Centre for MDR-TB, Hospital Centre Vila Nova de Gaia, Department of Pneumology, Public Health Science and Medical Education Department, Faculty of Medicine, University of Porto, Porto, Portugal
^S Division of Disease Prevention and Control, Department of Communicable Diseases, National Tuberculosis Control and Elimination Programme, Ministry of Health, Santiago, Chile
^T National Institute of Respiratory and Environmental Diseases Prof. Dr. Juan Max Boettner-Asunción, Paraguay
^U Universidad Autónoma de Baja California, Baja California, Mexico
^V Clínica de Tuberculosis del Hospital General de Tijuana, Tijuana, Baja California, Mexico
^W Internal Medicine Department, Hospital de Cantoblanco- Hospital General Universitario La Paz, Madrid, Spain
^X Pneumology Department, Tuberculosis Unit, Hospital de Cantoblanco- Hospital General Universitario La Paz, Madrid, Spain
^Y Centro de Investigación, Prevención y Tratamiento de Infecciones Respiratorias CIPTIR, University Hospital of Monterrey UANL (Universidad Autónoma de Nuevo León), Monterrey, Mexico
^Z National Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Catholic University Ruzomberok, Slovakia
^{aa} Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy
^{bb} Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna, Bologna, Italy
^{cc} Reference Center for MDR-TB and HIV-TB, Eugenio Morelli Hospital, Sondalo, Italy
^{dd} Zhejiang Integrated Traditional and Western Medicine Hospital, Hangzhou, China
^{ee} National TB Registry, Public Health Department, Ministry of Health, Vilnius, Lithuania
^{ff} Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
^{gg} Centro de Excelencia de TBMDR, Hospital Nacional Maria Auxiliadora, Lima, Peru
^{hh} Baylor College of Medicine, Children's Foundation, Mbabane, Eswatini
ⁱⁱ National Pharmacovigilance Center, Eswatini Ministry of Health, Matsapha, Eswatini
^{jj} Improve the Sustainability of the National TB Programme, Sofia, Bulgaria

^{kk} Department of Public Health Analysis and Data Management, Public Health Agency of Sweden, Solna, Sweden

^{ll} Eswatini National Aids Programme, Mbabane, Eswatini

^{mm} Hospital of Pneumophtisiology Leamna, Dolj Province, Romania

ⁿⁿ University of Medicine and Pharmacy, Craiova, Romania

^{oo} Respiratory Infectious Diseases Unit, Cotugno Hospital, A.O.R.N. dei Colli, Naples, Italy

^{pp} University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia

^{qq} Westmead Hospital, Sydney, Australia

^{rr} Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia

^{ss} Pneumology Department, Hospital General de Gran Canaria "Dr. Negrin", Las Palmas de Gran Canaria, Spain

^{tt} Vital Strategies, New York, USA

^{uu} Tuberculosis Research Programme (PII-TB), SEPAR, Barcelona, Spain

^{vv} Pediatric Clinic, Pietro Barilla Children's Hospital, University of Parma, Parma, Italy

^{ww} Clinical Epidemiology and Medical Statistics Unit, Department of z, University of Sassari, Sassari, Italy

^{xx} Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy

^{yy} Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, Tradate, Varese-Como, Italy

^{zz} Department of Infection, Royal London and Newham Hospitals, Barts Health NHS Trust, London, United Kingdom

^{AA} Department of Infectious Diseases, Galliera Hospital, Genova, Italy

^{BB} Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy

^{CC} Public Health Consulting Group, Lugano, Switzerland

^{DD} World Health Organization Regional office for Europe, Copenhagen, Denmark

Received 15 February 2021; accepted 15 February 2021

Available online 19 March 2021

KEYWORDS

Tuberculosis;
MDR-TB;
Delamanid;
Bedaquiline;
Treatment outcomes;
Prevention of TB
sequelae

Abstract The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis.

The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally.

This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year.

All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines.

Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10–80% in the remaining 5 countries).

The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3–7) in the overall cohort and 6 (4–8) among patients with a final outcome).

For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13–23) (in days 553 (385–678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30–90) days for the whole cohort and 60 (30–100) for patients with a final outcome and, respectively, of 55 (30–90) and 60 (30–90) days for culture conversion.

Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.

© 2021 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The World Health Organization (WHO) estimated that about half million people suffer from multidrug- (MDR-) or rifampicin-resistant (RR-) tuberculosis (TB) in 2019, of whom

38% accessed treatment and, among them, 57% were successfully treated.^{1,2}

Effective treatment, coupled with rapid and accurate diagnosis, of both drug-susceptible and -resistant (MDR- and extensively drug-resistant, XDR-) TB cases is an essential

intervention to curb the TB epidemic and prevent further development and transmission of drug-resistant *Mycobacterium tuberculosis* strains.^{3,4}

New drugs (*i.e.*, delamanid and bedaquiline) have been recently licensed to manage MDR- and XDR-TB²; they were included into a new WHO drug classification where bedaquiline belongs to Group A and delamanid to Group C.^{5–18}

Although more evidence is becoming available from experimental and observational studies on the efficacy and effectiveness of new drugs,^{19–23} programmatic information on their effectiveness is still incomplete worldwide.¹

The Global Tuberculosis Network (GTN) project,²⁴ which recently reported on the safety of these drugs, allowed to shed further light on the effectiveness of these drugs in a large cohort of patients (Table 1, Fig. 1).^{24–26}

The aim of the study is to prospectively evaluate the effectiveness of bedaquiline and/or delamanid-containing regimens in a cohort of consecutive TB patients treated globally.

Methods

Study design

The study is observational, prospective and based on the collection twice a year and analysis of data provided by GTN centres.

Following a pilot study implemented in 2015 to pre-test the project's feasibility, the results of the project (management of adverse events) was published elsewhere.^{25,26}

The study was approved by the Ethics Committee of the coordinating centre, and the participating centres obtained ethical clearance based on local regulations and signed a data-sharing agreement.^{25,26}

All consecutive patients (including children and adolescents) treated with bedaquiline and/or delamanid were enrolled either from the beginning of the study or from the time the drugs under study were introduced in the respective country centre (*e.g.* in Mexico, Nepal, Paraguay, Spain, Slovakia and Sudan).^{25,26}

In all participating countries, the patients were managed according to WHO and National guidelines, under supervision of a coordinating team supervising the patients' clinical management and validation of data.²⁷ Investigators were contacted by the coordinating centre to ensure accuracy after recoding and validation of the dataset before final analysis was conducted. Discrepancies were resolved by consensus.

WHO case and treatment outcome definitions were used.^{1,5,6,28,29}

The present manuscript reports the results of the interim analysis conducted on the data collected up to the 31st January 2021.

Variables collected

The data were collected *via* an *ad hoc* developed collection form in electronic format.^{25,26}

The information collected (from the clinical files of the participating centres) included, among others, anonymized

Table 1 Participating countries, estimated coverage and number of cases enrolled.

Countries	Estimated coverage ^a %	Cases enrolled N
Argentina	100	11
Australia ^c	100 ^e	26
Belarus ^b	80	53
Belgium	60	3
Brazil	100	39
Bulgaria	100	17
Chile	100	1
China ^c	100 ^d	5
Eswatini	100	41
Greece	100	6
India	100 ^e	15
Italy ^g	80	40
Latvia	100	30
Lithuania ^h	100	160
Mexico ⁱ	100	11
Nepal ^h	100	125
Netherlands ^b	100	6
Niger	100	17
Paraguay	100	1
Peru	80	29
Portugal	100	1
Romania ^c	100 ^f	7
Russian Federation ^b	100 ^j	202
Slovakia	100	1
Spain ^g	100	8
Sudan	100	2
Sweden	100	19
Switzerland	100 ^d	3
United Kingdom	10	4
Total 29	Range 10%–100%	Total 883

Legend:

^a Countries' estimate of the national coverage of the aDSM project on new drugs;

^b 2 centres;

^c 1 centre;

^d in the Province/Canton reporting;

^e in the State reporting;

^f in the Province reporting;

^g 7 centres;

^h 5 centres;

ⁱ 3 centres;

^j in the 2 Oblasts reporting.

patient's demographic data, bacteriological, radiological and clinical status at diagnosis, and details on bacteriological conversion and final treatment outcomes.

The study coverage and number of patients treated per centre are reported in Table 1.

Data analysis

A descriptive analysis was performed to evaluate the characteristics of the cohort.

Qualitative and quantitative variables were summarised using absolute and relative (percentage) frequencies, medians with interquartile ranges (IQR), and means with standard




Figure 1 Global distribution of the clinical centres participating in the study.

☆ The following States/Regions are covered in the study: Australia (State of Victoria); China (Zhejiang Province); Romania (Dolj Region); Russian Federation (Arkhangelsk, Moscow Oblasts).

deviations (SD). Sputum smear and culture conversion (as well as the time to sputum and culture conversion) were evaluated in the whole cohort and in those completing their prescribed regimen.

Treatment outcomes were evaluated only in patients who completed the prescribed treatment regimen (separately for the entire cohort and in patients treated with bedaquiline but not delamanid) to favour international comparisons.

Results

Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021 (Fig. 1).

Argentina, Australia (State of Victoria), Brazil, Bulgaria, Chile, Eswatini, China (Zhejiang Province), Greece, India, Latvia, Lithuania, Mexico, Nepal, The Netherlands, Niger, Paraguay, Portugal, Romania, Russian Federation (Moscow and Arkhangelsk Oblasts), Slovakia, Spain, Sudan, Sweden and Switzerland (Vaud county) reported 100% of the patients treated with new drugs in the country/region, while Belarus, Belgium, Italy, Peru and the United Kingdom reported a proportion of national patients ranging from 10% to 80% (Table 1).

Demographic, epidemiological, and clinical characteristics of the patients are summarised in Table 2. The bacteriological conversion rates and the time to sputum smear and culture conversion are reported in Table 3 separately for the entire cohort and for the patients completing their prescribed treatment regimen. The final treatment outcomes of the entire cohort (477/883, 54.0%) are summarized in Table 4, while Table 5 is reporting the patients treated with bedaquiline only who have a final outcome assigned.

Overall, 883 patients were treated with bedaquiline and/or delamanid, 477 of them with a final outcome assigned (Table 2).

Most patients were male ($n=602$, 68.2% in the overall cohort and $n=333$, 69.8% with a final outcome assigned) and the median (IQR) age was 38 (28–49) years for the entire cohort and (30–50) years for those with a final outcome.

The proportion of foreign born was 13.4% in the overall cohort and 12.8% in the group of patients with a final outcome. The main co-morbidities and risk factors are summarized in Table 2.

Pulmonary TB was diagnosed in 97% patients, and cavity lesions were found in over 60% of the patients' radiographs. Overall, there were 575/883 (65%) patients with MDR/RR-TB in the overall cohort, of whom 300/477 (62.9%) with a final outcome. Among them the XDR-TB cases were, respectively 289/883 (32.7%) and 169/477 (35.4%). Other resistance patterns were present only in 19/883 (2.2%) and 8/477 (1.7%), respectively.

The median (IQR) number of drugs for which resistance was detected was 5 (3–7) in the overall cohort and 6 (4–8) among patients with a final outcome.

Bedaquiline was administered to 782/883 patients in the entire cohort (88.6%), of whom 416/477 (87.2%) with a final outcome. The patients undergoing treatment with delamanid were, respectively 167/883 (18.9%) and 94/477 (19.7%), some of them having been treated also with bedaquiline.

The median (IQR) number of months of anti-TB treatment was 18 (13–23) (in days 553 (385–678)) among patients with a final outcome.

Bedaquiline was prescribed for 180 (168–264) days in the whole cohort and 183 (168–364) among patients with a final outcome. Delamanid was prescribed for 168 (144–184) days

Table 2 Characteristics of 883 patients undergoing treatment with bedaquiline and delamanid in the cohort, including 477 who completed the prescribed regimen.

Variable	All patients (n = 883)	Patients with final outcome (N = 477)
Male, n (%)	602/883 (68.2)	333/477 (69.8)
Median (IQR) age, years	38 (28–49)	39 (30–50)
Foreign born n (%)	118/882 (13.4)	61/477 (12.8)
Diabetes Mellitus, n (%)	79/880 (9.0)	40/476 (8.4)
People living with HIV, n (%)	67/871 (7.7)	27/473 (5.7)
Thyroid disease, n (%)	25/795 (3.1)	17/399 (4.3)
Alcohol misuse, n (%)	186/879 (21.2)	112/475 (23.6)
Injecting drug user n (%)	48/880 (5.5)	30/475 (6.3)
Methadone user, n (%)	10/787 (1.3)	4/395 (1.0)
Previous anti-TB treatment, n (%)	544/880 (61.8)	329/474 (69.4)
Surgical therapy, n (%)	90/814 (11.1)	59/449 (13.1)
Pulmonary TB, n (%)	857/883 (97.1)	463/477 (97.1)
Extra-pulmonary TB, n (%)	72/882 (8.2)	39/476 (8.2)
Cavitary lesions, n (%)	523/831 (62.9)	295/448 (65.8)
MDR/RR-TB, n (%)	575/883 (65.1)	300/477 (62.9)
XDR-TB, n (%)	289/883 (32.7)	169/477 (35.4)
Other drug-resistance patterns, n* (%)	19/883 (2.2)	8/477 (1.7)
Median (IQR) number of reported drug-resistances	5 (3–7)	6 (4–8)
Bdq administration, n (%)	782/883 (88.6)	416/477 (87.2)
Dlm administration, n (%)	167/883 (18.9)	94/477 (19.7)
Median (IQR) months anti-TB treatment duration	–	18 (13–23)
Median (IQR) days Bdq administration	180 (168–264)	183 (168–363,5)
Median (IQR) days Dlm administration	168 (144–184)	168 (136–186)

TB: tuberculosis; IQR: interquartile range; Bdq: bedaquiline; Dlm: delamanid; MDR/RR-TB: multi-drug resistant /rifampicin-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis.

* Including 3 susceptible cases treated with second-line drugs due to AEs first-line drugs.

Table 3 Sputum smear and culture conversion and median time to bacteriological conversion in 883 patients treated with new anti-tuberculosis drugs.

Variable	All patients (n = 883)	Patients with final outcome (N = 477)
Sputum smear conversion, n (%)	467/500 (93.4)	274/307 (89.3)
Sputum culture conversion, n (%)	532/573 (92.8)	324/365 (88.8)
Median (IQR) days sputum smear conversion	58 (30–90)	60 (30–100)
Median (IQR) days sputum culture conversion	55 (30–90)	60 (30–90)

IQR: interquartile range.

in the entire cohort and 168 (136–186) days to patients with a final outcome.

The proportion of patients achieving sputum smear conversion was 93.4% in the whole cohort and 89.3% among the patients with a final outcome, with a median (IQR) time to sputum smear and culture conversion of 58 (30–90) days for the whole cohort and 60 (30–100) for patients with a final outcome and, respectively, of 55 (30–90) and 60 (30–90) days as far as culture conversion is concerned (Table 3).

The final treatment outcomes of the entire cohort (477/883, 54.0%) are summarized in Table 4; 344/477 patients (72.1%) achieved treatment success, 38 died (8%), 20 failed (4.2%) and 75 (15.7%) were lost to follow-up.

Among the 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up (Table 5).

Discussion

The aim of the present study was to prospectively evaluate the outcome of a global cohort of patients treated with new anti-TB drugs.

Although new research results (some summarized in a special bedaquiline series of the IJTLD)^{19–23,30–35} have been recently published, to the best of our knowledge this is the first global study prospectively reporting detailed information on treatment outcomes; the report of the safety profile of the new drugs was published elsewhere.^{25,26}

The results of our study show that ~90% of patients from 29 countries in all continents, with a severe pattern of drug resistance (>30% with XDR-TB; median number of resistances: 5–6) achieved sputum smear and culture conversion within 60 days of treatment with new anti-TB drugs. The success rates achieved were 72.1% in the full cohort (patients

Table 4 Treatment outcomes of the 477 patients who completed the prescribed regimen including new anti-tuberculosis drugs.

Treatment Outcome	n/N (%)
Treatment success (cured + treatment completed)	344/477 (72.1)
Cured	281/477 (58.9)
Treatment completed	63/477 (13.2)
Died	38/477 (8.0)
Failure	20/477 (4.2)
Lost to follow-up	75/477 (15.7)

Table 5 Treatment outcomes of the 383 patients treated with bedaquiline (but no delamanid) who completed the prescribed regimen.

Treatment outcome	n/N (%)
Treatment success (cured + treatment completed)	284/383 (74.2)
Cured	226/383 (59.0)
Treatment completed	58/383 (15.1)
Died	25/383 (6.5)
Failure	11/383 (2.9)
Lost to follow-up	63/383 (16.5)

with a final outcome) and 74.2% among the patients (the vast majority) treated with bedaquiline. This second outcome is particularly relevant for international comparisons. Importantly, in this specific group of patients the death rate was 6.5%, the failure rate 2.9% and the lost to follow-up rate 16.5%; these outcomes need to be read considering that this cohort has been programmatically managed in many different settings, with a relatively low prevalence of HIV infection (5.7%). In a previous study by the GTN with different patients treated with bedaquiline,⁹ the culture conversion rate was similar (90%) and the overall success rate 76.9%

The study stratified the success rates by geographical area, showing that in austral Africa (where the HIV prevalence is higher) it was lower (64.6%) than in Niger (76.5%) where HIV prevalence is low, Europe (76.5%) and elsewhere (77.6%). Specifically in XDR-TB patients, the success rate was 77.6% in Africa, 80.4% in Europe and 77.7% elsewhere; these peculiar results, with treatment outcomes higher among XDR- than MDR-TB patients, have been caused by the fact that the XDR-TB patients had access to better drugs in the regimen (e.g. linezolid, clofazimine) which were not available in all countries (at the time the study was conducted) for MDR-TB patients. The WHO has from January 2021 updated its DR-TB definitions³⁶ to include the term pre-XDR for patients with an MDR-TB strain resistant to later generation fluoroquinolone and XDR-TB which is MDR-TB plus resistance to two group A drugs (fluoroquinolone plus bedaquiline or linezolid resistance). The MDR-TB definition remains the same.^{28,36}

Similarly, the death rate was much higher in Africa (23.9%) than in Europe (3.5%) and elsewhere (6.1%).

In a sub-group analysis of the 57 severe patients undergoing adjuvant surgery, the culture conversion rate was similar (90%) and the overall success rate 69.1%.³⁷

A South African study on 19,617 patients showed a 3-fold reduction of all-cause mortality among individuals treated with bedaquiline when compared with those treated without new drugs.³⁸

In the large individual patient data meta-analysis on 12,030 MDR-TB patients¹⁸ a small proportion of patients was treated with bedaquiline: 431/491 (87.8%) achieved treatment success (aOR, 95% CI: 2.0, 1.4–2.9) and 59/550 (10.7%) died (aOR, 95% CI: 0.4, 0.3–0.5).

The preliminary results of the Challenge-TB Project³⁰ reported, among bedaquiline-treated patients, a culture conversion of 71% at months 6, with 58.8% treatment success, 11.8% failure, 23.5% died, 4.7% lost to follow-up and 1.2% still on treatment after 24 months (2016 cohort data). The patients' drug resistance profile was not reported.³⁰ The project involved 23 countries with 9389 patients enrolled between 2016 and mid-2019. Among the most relevant problems encountered, the Authors identified the limited in-country coordination and the absence of a robust clinical and laboratory network and the difficulties of implementing effective monitoring of adverse events related to the new drugs.^{25,26}

A report from India (interim analysis) showed 83% culture conversion rate among the patients treated with bedaquiline within a median time of 60 days, while the final outcomes were not yet available.³³

In Eswatini, between 2015 and 2018, 355 patients started treatment with new drugs (bedaquiline and/or delamanid), of whom 109 were treated with bedaquiline only and with final outcomes.³⁵ Out of 109 patients, 80 were treated successfully (73.4%, a result consistent with that of our study), 18 died (16.5%, higher than our death rate but the HIV prevalence was higher in Eswatini, 72.3%), 1 failed, 1 was lost to follow-up (both 0.9%) and 9 were still in treatment after 24 months (8.3%). In the Eswatini cohort the proportion of males (58–7%), the median (IQR) age (35 (29–44) years) and the proportion of pre-XDR-/XDR-TB patients (26–1%) was consistent with our study.

Although without reporting details on treatment outcomes some studies have started reporting on the modified shorter regimens, which include bedaquiline to replace the injectable drug in the former Bangladesh regimen.^{20,31,34}

The project worked as a 'register' reporting treatment outcomes (and aDSM findings)^{25,26} twice a year so as to support countries in implementing quality monitoring and evaluation of the process of introducing new anti-TB drugs under programmatic conditions.

The study has several strengths, including the number of countries participating (29) from all continents, a large sample size (as far we know one of the largest studies of its kind), the prospective design, and the accuracy of the information collected. Last but not least, the majority of countries/states/regions (24/29) provided data on all the consecutive patients treated with bedaquiline and delamanid during the study period.

One limitation (common to all the studies of this kind) is the impossibility of attributing the outcomes to a specific drug, as treatment regimens are inherently polypharmacological.

A second limitation is that few paediatric patients (twenty-seven individuals aged less than 18 years) and people living with HIV (n = 67; 7.7%) were included in the cohort to allow specific sub-analyses.

The study will continue to evaluate early and final treatment outcomes as periodic updates occur and the 'cohort' is therefore a 'living' one. This cohort allows evaluation of novel treatments and combinations in a relatively short time-frame – particularly important given the substantial variation in international practice and guidelines recommending person-centered therapy for MDR-TB.^{4,5,39–41}

This approach will allow the participating countries to evaluate the 'quality' of their treatment services and minimise the risk of post-treatment sequelae responsible of functional damage and impaired quality of life.^{42–48}

In conclusion, our Global TB Network study further supports the importance of access to lifesaving anti-TB drugs like bedaquiline to improve outcome of drug-resistant (DR) TB patients. Bedaquiline has allowed for an all-oral, less toxic shorter regimen which significantly improves survival, and it is becoming more widely available globally.⁴⁹ Future cohort reviews will show a reduction of treatment duration from 18 months to 6 months. This global study shows that even when there is access to the same WHO DR TB regimen, outcomes can still differ greatly, highlighting that managing MDR-/DR-TB is not only a question of better detection of DR-TB and starting treatment. Even though the WHO has shortened treatment considerably for the majority of DR-TB patients, it is very likely that more work and investment are required, especially in resource limited settings and treatment of people living with HIV and to combat the small but concerning number of XDR-TB patients.

Authors' contribution

The manuscript was conceived, planned, written, edited and approved using a collaborative approach, following the internal GTN (Global Tuberculosis Network) and internationally acknowledged rules on Authorship, based on major intellectual contribution to the steps mentioned above. The study represents a global effort involving 26 countries in all continents.

Giovanni Sotgiu, Simon Tiberi, Rosella Centis, Lia D'Ambrosio and Giovanni Battista Migliori wrote the protocol. Giovanni Sotgiu, Laura Saderi and Raquel Duarte revised it for the methodological content.

Giovanni Sotgiu, Laura Saderi, Rosella Centis and Lia D'Ambrosio performed the analysis.

Simon Tiberi, Rosella Centis, Lia D'Ambrosio, Emanuele Pontali, Jan-Willem Alffenaar, Jose A. Caminero, Giovanni Sotgiu and Giovanni Battista Migliori wrote the first draft of the manuscript.

Sushil Koirala, Sergey Borisov, Judith Bruchfeld, Alberto Piubello, Onno Akkermann, Justin Denholm, José-María García-García, Rafael Laniado-Laborín, Jessica Mazza-Stalder, Alberto Matteelli, Marcela Muñoz-Torrico, Martin van den Boom, Dina Visca, Jose A. Caminero, Giovanni Sotgiu wrote the sections of the manuscript (second draft).

Antonio Spanevello, José-María, García-García Zarir Farokh Udwadia, Edvardas Danila, Andrei Maryandyshev,

Susanna Esposito and Margareth Dalcolmo provided comments to the second draft (third draft).

Bhabana Shrestha, Satya Raj Shakya, Hikmat Bahadur Khadka, Ghan Shyam Koirala, Rajesh GC, Skaidrius Miliuskas, Liga Kukša, Selene Manga, Alena Skrahina, Saulius Diktanas, Luigi Ruffo Codecasa, Alena Aleksa, Antoniya Koleva, Evgeny Belilovski, Enrique Bernal, Martin J Boeree, Julen Cadiñanos Loidi, Qingshan Cai, Jose Joaquín Cebrian Gallardo, Moschos Charalampos, Edita Davidavičienė, Lina Davies Forsman, Jorge De Los Rios Jefe, Alemayehu Duga, Seifeldin Eltaeb Elamin, Nadia Escobar Salinas, Maurizio Ferrarese, Aleksey Filippov, Blagovesta Gadzheva, Ana Garcia, Ieva Gaudiesiute, Regina Gayoso, Roscio Gomez Rosso, Vyngantas Gruslys, Gina Gualano, Wouter Hoefstoot, Victor Ionel Grecu, Jerker Jonsson, Elena Khimova, Heinke Kunst, Yang Li, Nomthandazo Lukhele, Cecile Magis-Escurra, Gugulethu Madonsela, Vinicio Manfrin, Valentina Marchese, Elena Martínez Robles, Andrei Maryandyshev, Marius Matei, Ilaria Motta, Hamdan Mustafa Hamdan, Biruté Nakčerienė, Lauren Nicod, Magnolia Nieto Marcos, Domingo Juan Palmero, Fabrizio Palmieri, Apostolos Papavasileiou, Marie-Christine Payen, Agostina Pontarelli, Sarai Quirós, Adrian Rendon, Laura Saderi, Agnese Šmite, Ivan Solovic, Mahamadou Bassirou Souleymane, Marina Tadolini, Marisa Vescovo, Piero Viggiani, Rolandas Zablockis, Dmitry Zhurkin and provided additions to the fourth draft.

Simon Tiberi and Justin Denholm proof read the manuscript.

All co-Authors approved the final manuscript.

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval

Ethical approval was obtained by the coordinating centre and in each country as per national regulations in force.

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgements

The project is supported by the Global Tuberculosis Network (GTN; Committees on TB Treatment, Clinical trials and Global TB Consilium) and was part of the European Respiratory Society Latin American project in collaboration with ALAT (Asociación Latino Americana de Torax - Latino American Thoracic Association) and SBPT (Brazilian Society of Pulmonology and Tuberculosis).

This article belongs to the scientific activities of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020- GBM/RC/LDA.

The Authors wish to thank Dr. Algirdas Gauronskis, Dr. Vita Globytė (Clinic of Tuberculosis and Pulmonology, Republican Šiauliai county hospital, Šiauliai, Lithuania), Dr. Antanas Strazdas (Department of Tuberculosis, Alytus

County Tuberculosis Hospital, Alytus, Lithuania), Dr. Paola Castellotti (Regional TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy), Ms. Samridhi Karki (Kalimati Chest Hospital/ GENETUP NATA, Nepal), Dr Andrea Calcagno, Alberto Gaviraghi and Francesca Alladio (Department of Medical Science, Unit of Infectious Diseases, University of Torino, Italy) for their contribution.

References

- World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Available at: <https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf> Accessed 9 December 2020.
- Pontali E, Raviglione MC, Migliori GB, The writing group members of the Global TB Network Clinical Trials Committee. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. *Eur Respir Rev.* 2019;28(152):190035, <http://dx.doi.org/10.1183/16000617.0035-2019>.
- Migliori GB, Nardell E, Yedilbayev A, D'Ambrosio L, Centis R, Tadolini M, et al. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. *Eur Respir J.* 2019;53(6):1900391, <http://dx.doi.org/10.1183/13993003.00391-2019>.
- Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. *Int J Infect Dis.* 2020;92S:S15–25, <http://dx.doi.org/10.1016/j.ijid.2020.01.042>.
- World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
- Migliori GB, Global Tuberculosis Network (GTN). Evolution of programmatic definitions used in tuberculosis prevention and care. *Clin Infect Dis.* 2019;68(10):1787–9, <http://dx.doi.org/10.1093/cid/ciy990>.
- Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. *N Engl J Med.* 2014;371(8):723–32, <http://dx.doi.org/10.1056/NEJMoa1313865>.
- Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, et al. TMC207-C209 Study Group. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. *Eur Respir J.* 2016;47(2):564–74.
- Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study. *Eur Respir J.* 2017;49(5):1700387, <http://dx.doi.org/10.1183/13993003.00387-2017>.
- Pontali E, Sotgiu G, D'Ambrosio L, Centis R, Migliori GB. Bedaquiline and MDR-TB: a systematic and critical analysis of the evidence. *Eur Respir J.* 2016;47:394–402.
- Pontali E, D'Ambrosio L, Centis R, Sotgiu G, Migliori GB. Multidrug-resistance tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. *Eur Respir J.* 2017;49(3):1700146, <http://dx.doi.org/10.1183/13993003.00146-2017>.
- Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, et al. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. *Emerg Infect Dis.* 2019;25(5):936–43, <http://dx.doi.org/10.3201/eid2505.181823>.
- Chesov D, Heyckendorf J, Alexandru S, Donica A, Chesov E, Reiman M, et al. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. *Eur Respir J.* 2020, <http://dx.doi.org/10.1183/13993003.02544-2020>. Dec 17:2002544.
- Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. *N Engl J Med.* 2012;366(23):2151–60, <http://dx.doi.org/10.1056/NEJMoa1112433>.
- Kim CT, Kim CTO, Shin HJ, Ko YC, Hun Choe Y, Kim HR, et al. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multi-center cohort study in Korea. *Eur Respir J.* 2018;51(3):1702467, <http://dx.doi.org/10.1183/13993003.02467-2017>.
- Kuksa L, Barkane L, Hittel N, Gupta R. Final treatment outcomes of multidrug and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens. *Eur Respir J.* 2017;50(5):1701105, <http://dx.doi.org/10.1183/13993003.01105-2017>.
- Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, et al. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. *Eur Respir J.* 2018;51(6):1800017, <http://dx.doi.org/10.1183/13993003.00017-2018>.
- Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. *Lancet.* 2018;392(10150):821–34, [http://dx.doi.org/10.1016/S0140-6736\(18\)31644-1](http://dx.doi.org/10.1016/S0140-6736(18)31644-1).
- Bernal O, Lopez R, Montoro E, Avedillo P, Westby K, Ghidinelli M. Introduction and scaling up of new drugs for drug-resistant TB: experiences from the Americas. *Int J Tuberc Lung Dis.* 2020;24(10):1058–62, <http://dx.doi.org/10.5588/ijtld.20.0111>.
- Cox H, Shah NS, Castro KG. Discovering a new drug is only the beginning: progress and challenges in expanding access to BDQ for MDR-TB treatment. *Int J Tuberc Lung Dis.* 2020;24(10):985–6, <http://dx.doi.org/10.5588/ijtld.20.0562>.
- Rutta E, Kambili C, Mukadi Y. The Bedaquiline donation program: progress and lessons learned after 4 years of implementation. *Int J Tuberc Lung Dis.* 2020;24(10):1039–45, <http://dx.doi.org/10.5588/ijtld.20.0134>.
- Lachenal N, Hewison C, Mitnick C, Lomtadze N, Coutisson S, Osso E, et al. Setting up pharmacovigilance based on available endTB Project data for bedaquiline. *Int J Tuberc Lung Dis.* 2020;24(10):1087–94, <http://dx.doi.org/10.5588/ijtld.20.0115>.
- Seung KJ, Khan U, Varaine F, Ahmed S, Bastard M, Cloez S, et al. Introducing new and repurposed TB drugs: the endTB experience. *Int J Tuberc Lung Dis.* 2020;24(10):1081–6, <http://dx.doi.org/10.5588/ijtld.20.0141>.
- Silva DR, Rendon A, Alffenaar JW, Chakaya JM, Sotgiu G, Esposito S, et al. Global TB Network: working together to eliminate tuberculosis. *J Bras Pneumol.* 2018;44(5):347–9, <http://dx.doi.org/10.1590/S1806-3756201800000279>.
- Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, et al. Members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: a global feasibility study. *Int J Infect Dis.* 2019;83:72–6, <http://dx.doi.org/10.1016/j.ijid.2019.03.036>.
- Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculo-

- sis: first global report. *Eur Respir J.* 2019;54(6):1901522, <http://dx.doi.org/10.1183/13993003.01522-2019>.
27. Tiberi S, Pontali E, Tadolini M, D'Ambrosio L, Migliori GB. Challenging MDR-TB clinical problems – the case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. *Int J Infect Dis.* 2019;80S:S68–72, <http://dx.doi.org/10.1016/j.ijid.2019.01.040>.
 28. World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014 and January 2020). Geneva: World Health Organization; 2013. WHO/HTM/TB/2013.2. Available at: <https://www.who.int/tb/publications/definitions/en> Accessed 4 February 2021.
 29. Avaliani Z, Gozalov O, Kuchukhidze G, Skrahina A, Soltan V, van den Boom M, et al. What is behind programmatic treatment outcome definitions for tuberculosis? *Eur Respir J.* 2020;56(1):2001751, <http://dx.doi.org/10.1183/13993003.01751-2020>.
 30. Edwards CG, Wares DF, Dravniece G, Gebhard A, Tiemersma E, van der Grinten E, et al. Introducing bedaquiline: experiences from the Challenge TB Project. *Int J Tuberc Lung Dis.* 2020;24(10):1046–53, <http://dx.doi.org/10.5588/ijtld.19.0790>.
 31. Zabsonre I, Thi SS, Cox V. Overcoming barriers to the access and uptake of newer drugs for multidrug-resistant TB. *Int J Tuberc Lung Dis.* 2020;24(10):1054–7, <http://dx.doi.org/10.5588/ijtld.20.0226>.
 32. Santiago MR, Garfin AMC, Balanag VM. Introduction of bedaquiline for the treatment of drug-resistant TB in the Philippines. *Int J Tuberc Lung Dis.* 2020;24(10):1063–6, <http://dx.doi.org/10.5588/ijtld.20.0359>.
 33. Sachdeva KS, Arora N, Solanki R, Singla R, Sarin R, Bhatnagar A, et al. Strengthened capacity of India's bedaquiline Conditional Access Programme for introducing new drugs and regimens. *Int J Tuberc Lung Dis.* 2020;24(10):1067–72, <http://dx.doi.org/10.5588/ijtld.20.0136>.
 34. Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M, Ferreira H, et al. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn? *Int J Tuberc Lung Dis.* 2020;24(10):1073–80, <http://dx.doi.org/10.5588/ijtld.20.0174>.
 35. Vambe D, Kay AW, Furin J, Howard AA, Dlamini T, Dlamini N, et al. Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini. *Int J Tuberc Lung Dis.* 2020;24(10):1095–102, <http://dx.doi.org/10.5588/ijtld.20.0082>.
 36. World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020. Geneva: World Health Organization; 2021. CC BY-NC-SA 3.0 IGO.
 37. Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, et al. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. *J Infect.* 2019;78(1):35–9, <http://dx.doi.org/10.1016/j.jinf.2018.08.003>.
 38. Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. *Eur Respir J.* 2018;52(6):1801528, <http://dx.doi.org/10.1183/13993003.01528-2018>.
 39. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. STREAM Study Collaborators. A trial of a shorter regimen for rifampin-resistant tuberculosis. *N Engl J Med.* 2019;380(13):1201–13, <http://dx.doi.org/10.1056/NEJMoa1811867>.
 40. Churchyard GJ. A short regimen for rifampin-resistant tuberculosis. *N Engl J Med.* 2019;380(13):1279–80, <http://dx.doi.org/10.1056/NEJMe1902904>.
 41. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis. An Official ATS/CDC/ERS/IDSA clinical practice guideline. *Am J Respir Crit Care Med.* 2019;200(10):e93–142, <http://dx.doi.org/10.1164/rccm.201909-1874ST>.
 42. Muñoz-Torrico M, Rendon A, Centis R, D'Ambrosio L, Fuentes Z, Torres-Duque C, et al. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis? *J Bras Pneumol.* 2016;42(5):374–85, <http://dx.doi.org/10.1590/S1806-37562016000000226>.
 43. Tiberi S, Torrico MM, Rahman A, Krutikov M, Visca D, Silva DR, et al. Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. *J Bras Pneumol.* 2019;45(2):e20180324, <http://dx.doi.org/10.1590/1806-3713/e20180324>.
 44. Visca D, Zampogna E, Sotgiu G, Centis R, Sadari L, D'Ambrosio L, et al. Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. *Eur Respir J.* 2019;53(3):1802184, <http://dx.doi.org/10.1183/13993003.02184-2018>.
 45. Visca D, Centis R, Muñoz-Torrico M, Pontali E. Post-tuberculosis sequelae: the need to look beyond treatment outcome. *Int J Tuberc Lung Dis.* 2020;24(8):761–2.
 46. Visca D, Centis R, D'Ambrosio L, Muñoz-Torrico M, Chakaya JM, Tiberi S, et al. The need for pulmonary rehabilitation following tuberculosis treatment. *Int J Tuberc Lung Dis.* 2020;24(7):720–2.
 47. Muñoz-Torrico M, Cid-Juárez S, Gochicoa-Rangel L, Torrebouscolet L, Salazar-Lezama MA, Villarreal-Velarde H, et al. Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis.* 2020;24(7):700–5.
 48. Akkerman OW, Ter Beek L, Centis R, Maeurer M, Visca D, Muñoz-Torrico M, et al. Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. *Int J Infect Dis.* 2020;92S:S10–4, <http://dx.doi.org/10.1016/j.ijid.2020.01.029>.
 49. Natarajan S, Singla R, Singla N, Gupta A, Caminero JA, Chakraborty A, et al. Treatment interruption patterns and adverse events among patients on bedaquiline containing regimen underprogrammatic conditions in India. *Pulmonology.* 2020;S2531–0437(20), <http://dx.doi.org/10.1016/j.pulmoe.2020.09.006>, 30213-0.